Unknown

Dataset Information

0

Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management.


ABSTRACT: We evaluated for the first time, to our knowledge, adverse health outcomes (AHOs) among US testicular cancer survivors (TCS) given chemotherapy (n?=?381) vs surgery-only patients (n?=?98) managed at a single institution, accounting for non-treatment-related risk factors to delineate chemotherapy's impact. Chemotherapy consisted largely of bleomycin-etoposide-cisplatin (BEP) administered in three or four cycles (BEPx3, n?=?235; BEPx4, n?=?82). Incidence of at least 3 AHOs was lowest in surgery-only TCS and increased with BEPx3, BEPx4, and other cisplatin-based regimens (12.2%, 40.8%, 52.5%, 54.8%; P?

SUBMITTER: Agrawal V 

PROVIDER: S-EPMC7065712 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management.

Agrawal Vaibhav V   Dinh Paul C PC   Fung Chunkit C   Monahan Patrick O PO   Althouse Sandra K SK   Norton Kelli K   Cary Clint C   Einhorn Lawrence L   Fossa Sophie D SD   Adra Nabil N   Travis Lois B LB  

JNCI cancer spectrum 20191008 2


We evaluated for the first time, to our knowledge, adverse health outcomes (AHOs) among US testicular cancer survivors (TCS) given chemotherapy (n = 381) vs surgery-only patients (n = 98) managed at a single institution, accounting for non-treatment-related risk factors to delineate chemotherapy's impact. Chemotherapy consisted largely of bleomycin-etoposide-cisplatin (BEP) administered in three or four cycles (BEPx3, n = 235; BEPx4, n = 82). Incidence of at least 3 AHOs was lowest in surgery-on  ...[more]

Similar Datasets

| S-EPMC7368467 | biostudies-literature
| S-EPMC6712564 | biostudies-literature
| S-EPMC5835297 | biostudies-literature
| S-EPMC9263534 | biostudies-literature
| S-EPMC6345519 | biostudies-literature
| S-EPMC7686327 | biostudies-literature
2023-09-06 | GSE216357 | GEO
| S-EPMC10417151 | biostudies-literature
| S-EPMC4854770 | biostudies-literature
| S-EPMC7315098 | biostudies-literature